Glycosylation of the c-Myc transactivation domain - PubMed (original) (raw)
Glycosylation of the c-Myc transactivation domain
T Y Chou et al. Proc Natl Acad Sci U S A. 1995.
Abstract
O-linked N-acetylglucosamine (O-GlcNAc) is an abundant and dynamic posttranslational modification composed of a single monosaccharide, GlcNAc, glycosidically composed of a single monosaccharide, GlcNAc, glycosidically linked to the side-chain hydroxyl of serine or threonine residues. Although O-GlcNAc occurs on a myriad of nuclear and cytoplasmic proteins, only a few have thus far been identified. These O-GlcNAc-bearing proteins are also modified by phosphorylation and form reversible multimeric complexes. Here we present evidence for O-GlcNAc glycosylation of the oncoprotein c-Myc, a helix-loop-helix/leucine zipper phosphoprotein that heterodimerizes with Max and participates in the regulation of gene transcription in normal and neoplastic cells. O-GlcNAc modification of c-Myc is shown by three different methods: (i) demonstration of lectin binding to in vitro translated protein using a protein-protein interaction mobility-shift assay; (ii) glycosidase or glycosyltransferase treatment of in vitro translated protein analyzed by lectin affinity chromatography; and (iii) direct characterization of the sugar moieties on purified recombinant protein overexpressed in either insect cells or Chinese hamster ovary cells. Analyses of serial deletion mutants of c-Myc further suggest that the O-GlcNAc site(s) are located within or near the N-terminal transcription activation/malignant transformation domain, a region where mutations of c-Myc that are frequently found in Burkitt and AIDS-related lymphomas cluster.
Similar articles
- c-Myc is glycosylated at threonine 58, a known phosphorylation site and a mutational hot spot in lymphomas.
Chou TY, Hart GW, Dang CV. Chou TY, et al. J Biol Chem. 1995 Aug 11;270(32):18961-5. doi: 10.1074/jbc.270.32.18961. J Biol Chem. 1995. PMID: 7642555 - Reconstitution of an E box-binding Myc:Max complex with recombinant full-length proteins expressed in Escherichia coli.
Farina A, Faiola F, Martinez E. Farina A, et al. Protein Expr Purif. 2004 Apr;34(2):215-22. doi: 10.1016/j.pep.2003.11.021. Protein Expr Purif. 2004. PMID: 15003254 Free PMC article. - Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.
Greis KD, Gibson W, Hart GW. Greis KD, et al. J Virol. 1994 Dec;68(12):8339-49. doi: 10.1128/JVI.68.12.8339-8349.1994. J Virol. 1994. PMID: 7966627 Free PMC article. - O-linked N-acetylglucosamine and cancer: messages from the glycosylation of c-Myc.
Chou TY, Hart GW. Chou TY, et al. Adv Exp Med Biol. 2001;491:413-8. doi: 10.1007/978-1-4615-1267-7_26. Adv Exp Med Biol. 2001. PMID: 14533811 Review. - Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription.
Kamemura K, Hart GW. Kamemura K, et al. Prog Nucleic Acid Res Mol Biol. 2003;73:107-36. doi: 10.1016/s0079-6603(03)01004-3. Prog Nucleic Acid Res Mol Biol. 2003. PMID: 12882516 Review.
Cited by
- O-GlcNAcylation in tumorigenesis and its implications for cancer therapy.
Zhang D, Qi Y, Inuzuka H, Liu J, Wei W. Zhang D, et al. J Biol Chem. 2024 Sep;300(9):107709. doi: 10.1016/j.jbc.2024.107709. Epub 2024 Aug 22. J Biol Chem. 2024. PMID: 39178944 Free PMC article. Review. - O-GlcNAcylation: cellular physiology and therapeutic target for human diseases.
Ye L, Ding W, Xiao D, Jia Y, Zhao Z, Ao X, Wang J. Ye L, et al. MedComm (2020). 2023 Dec 19;4(6):e456. doi: 10.1002/mco2.456. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38116061 Free PMC article. Review. - Deciphering the Properties and Functions of Glycoproteins Using Quantitative Proteomics.
Xu S, Xu X, Wu R. Xu S, et al. J Proteome Res. 2023 Jun 2;22(6):1571-1588. doi: 10.1021/acs.jproteome.3c00015. Epub 2023 Apr 3. J Proteome Res. 2023. PMID: 37010087 Free PMC article. Review. - O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner.
Yang Y, Yan Y, Yin J, Tang N, Wang K, Huang L, Hu J, Feng Z, Gao Q, Huang A. Yang Y, et al. Signal Transduct Target Ther. 2023 Feb 10;8(1):63. doi: 10.1038/s41392-023-01316-8. Signal Transduct Target Ther. 2023. PMID: 36765030 Free PMC article. - Improved antitumor activity against prostate cancer via synergistic targeting of Myc and GFAT-1.
Zhang Y, Li J, Huang Y, Chen Y, Luo Z, Huang H, West RE 3rd, Nolin TD, Wang Z, Li S. Zhang Y, et al. Theranostics. 2023 Jan 1;13(2):578-595. doi: 10.7150/thno.76614. eCollection 2023. Theranostics. 2023. PMID: 36632215 Free PMC article.
References
- J Biol Chem. 1992 May 25;267(15):10470-80 - PubMed
- J Cell Biol. 1987 May;104(5):1157-64 - PubMed
- FASEB J. 1992 Sep;6(12):3065-72 - PubMed
- J Biol Chem. 1993 May 15;268(14):10416-24 - PubMed
- Oncogene. 1993 Oct;8(10):2741-8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources